About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Imatinib TDM in GIST | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 2NCT05493215

Imatinib TDM in GIST

Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. Th...

Lead sponsor: Reema A. Patel•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Yvonne A Taul, RN

CONTACT

859-323-2354 [email protected]

Sponsors

Lead Sponsor

Reema A. Patel

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)
•Currently receiving imatinib initiated within the last 3 months or to be started in the next 1 month
•Prior systemic chemotherapy for other malignancy is allowed as long as it was completed within the past 6 months and there is no evidence of disease
•Age ≥18 years
•ECOG performance status of 0 or 1
•Normal organ function

Exclusion Criteria

•Presence of PDGFRA D842V mutation
•Known allergy to imatinib or allergic reactions to compounds of similar chemical or biologic composition to the study drug
•Concomitant anticoagulation with oral warfarin.
•Use of strong inhibitors or inducers of CYP3A or CYP3A4, drugs metabolized by CYP3A4 or CYP2D6
•Uncontrolled intercurrent illness
•Concurrent malignancy

Related studies

RECRUITINGPhase 1/2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

RECRUITINGPhase 2

GIST Oral Paclitaxel(Liporaxel)

NCT06326346 · Gastrointestinal Stromal Tumors

RCT of EFTR Versus STER for GIST Treatment

NCT07411118 · Small Size Gastrointestinal Stromal Tumors, GIST

RECRUITINGPhase 2

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

NCT05385549 · Gastrointestinal Stromal Tumors

Observational Registry Data on GIST Patients

NCT03602092 · Gastrointestinal Stromal Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 17, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment28

Start dateMar 2024

Last updatedFeb 17, 2026

Condition

Gastrointestinal Stromal Tumors

Locations shown

Markey Cancer Center

Lexington, Kentucky

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions